Top

Drug Safety

Published in:

01-09-2004 | Review Article

Drug Interactions with St John’s Wort

Mechanisms and Clinical Implications

Author: Dr Marcus Mannel

Published in: Drug Safety | Issue 11/2004

Abstract

The purpose of this paper is to review preclinical and clinical evidence relating to drug interactions with preparations of the medicinal herb St John’s wort (Hypericum perforatum). A systematic literature search was carried out in three electronic databases up to June 2004. Information about case reports classified as St John’s wort drug interactions was retrieved from the WHO Collaborating Centre for International Drug Monitoring and from the UK Medicines and Healthcare products Regulatory Agency in June 2003.

Against the background of proven efficacy in mild to moderate depressive disorders and an excellent tolerability profile in monotherapy, there is sufficient evidence from interaction studies and case reports to suggest that St John’s wort may induce the cytochrome P450 (CYP) 3A4 enzyme system and the P-glycoprotein drug transporter in a clinically relevant manner, thereby reducing efficacy of co-medications. Drugs most prominently affected and contraindicated for concomitant use with St John’s wort are metabolised via both CYP3A4 and P-glycoprotein pathways, including HIV protease inhibitors, HIV non-nucleoside reverse transcriptase inhibitors (only CYP3A4), the immunosuppressants ciclosporin and tacrolimus, and the antineoplastic agents irinotecan and imatinib mesylate. Efficacy of hormonal contraceptives may be impaired as reflected by case reports of irregular bleedings and unwanted pregnancies. Drugs with a narrow therapeutic index should be monitored more closely when St John’s wort is added, discontinued or the dosage is changed. The St John’s wort constituent hyperforin is probably responsible for CYP3A4 induction via activation of a nuclear steroid/pregnane and xenobiotic receptor (SXR/PXR) and hypericin may be assumed to be the P-glycoprotein inducing compound, although the available evidence is less convincing.

Combinations of St John’s wort with serotonergic agents and other antidepressants should be restricted to prescription-only, by experienced clinicians, due to potential central pharmacodynamic interactions.

In conclusion, providing certain precautions and contraindications are followed, and adequate information is given to healthcare professionals and patients, the safe and effective use of quality-tested St John’s wort products can be ensured.

Roth L. Hypericum, Hypericin. Botanik, Inhaltsstoffe, Wirkung. Landsberg: Ecomed, 1990: 125–9

Barnes J, Anderson LA, Phillipson JD. St John’s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001 May; 53(5): 583–600PubMedCrossRef

Bilia AR, Gallori S, Vincieri FF. St John’s wort and depression: efficacy, safety and tolerability: an update. Life Sci 2002 May 17; 70(26): 3077–96PubMedCrossRef

Kim HL, Streltzer J, Goebert D. St John’s wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 1999; 187: 532–9PubMedCrossRef

Linde K, Mulrow CD. St John’s wort for depression (Cochrane Review). Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 5. Oxford: Update Software, 2001

Whiskey E, Werneke U, Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review. Int Clin Psychopharmacol 2001; 16: 239–52PubMedCrossRef

Williams Jr JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132: 743–56743-56PubMed

Arzneimittelkommission der Deutschen Arzteschaft (ed). Empfehlungen zur Therapie der Depression [Drug Commission of the German Medical Association (ed.). Recommendations for the treatment of depression]. In: Arzneiverordnung in der Praxis, Sonderheft 8. Koln: Arzneimittelkommission der Deutschen Arzteschaft, 1997

Volz HP, Murck H, Kasper S, et al. St John’s wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology 2002; 164: 294–300PubMedCrossRef

10.

Müller T, Mannel M, Murck H, et al. Treatment of somatoform disorders with St John’s wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 2004; 66(4): 538–47PubMedCrossRef

11.

Stevinson C, Ernst E. A pilot study of Hypericum perforatum for the treatment of premenstrual syndrome. Br J Obstet Gynaecol 2000; 107: 870–6CrossRef

12.

Taylor LH, Kobak KA. An open-label trial of St John’s wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 2000; 61: 575–8PubMedCrossRef

13.

Friede M, Wustenberg P. Johanniskraut zur Therapie von Angstsyndromen bei depressiven Verstimmungen. Z Phytother 1998; 19: 309–17

14.

Kasper S, Dienel A. Cluster analysis of symptoms during antidepressant treatment with Hypericum extract in mildly to moderately depressed out-patients: a meta-analysis of data from three randomized, placebo-controlled trials. Psychopharmacology 2002; 164: 301–8PubMedCrossRef

15.

Davidson JR, Connor KM. St John’s wort in generalized anxiety disorder: three case reports. J Clin Psychopharmacol 2001; 21: 635–6PubMedCrossRef

16.

Winkel R, Koritsch HD, Piayda H, et al. St John’s wort extract LI 160 in depressive, alcohol-addicted patients [abstract]. Phytomedicine 2000; 7Suppl. 2: 19

17.

Hubner WD, Kirste T. Experience with St John’s wort (Hypericum perforatum) in children under 12 years with symptoms of depression and psychovegetative disturbances. Phytother Res 2001; 15: 367–70367-70PubMedCrossRef

18.

Greeson JM, Sanford B, Monti DA. St John’s wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology (Berl) 2001 Feb; 153(4): 402–14CrossRef

19.

Muller WE. Current St John’s wort research from mode of action to clinical efficacy. Pharmacol Res 2003 Feb; 47(2): 101–9PubMedCrossRef

20.

Czekalla J, Gastpar M, Hubner WD, et al. The effect of hypericum extract on cardiac conduction as seen in the electrocardiogram compared to that of imipramine. Pharmacopsychiatry 1997; 30Suppl. 2: 86–8PubMedCrossRef

21.

Dimpfel W, Todorova A, Vonderheid-Guth B. Pharmacodynamic properties of St John’s wort: a single-blind neurophysiological study in healthy subjects comparing two commercial preparations. Eur J Med Res 1999; 4: 303–12PubMed

22.

Schmidt U, Sommer H. Johanniskraut-Extrakt zur ambulanten Therapie der Depression. Fortschr Med 1993; 111: 339–42PubMed

23.

Ernst E, Rand JI, Barnes J, et al. Adverse effect profile of the herbal antidepressant St John’s wort (Hypericum perforatum L.). Eur J Clin Pharmacol 1998; 54: 589–94PubMedCrossRef

24.

Stevinson C, Ernst E. Safety of hypericum in patients with depression: a comparison with conventional antidepressants. CNS Drugs 1999 Feb; 11(2): 125–32CrossRef

25.

Hubner WD, Arnoldt KH. St John’s wort: a one year treatment study [in German]. Z Phytother 2000; 21: 306–10

26.

Schulz V. Incidence and clinical relevance of the interactions and side effects of Hypericum preparations. Phytomedicine 2001 Mar; 8(2): 152–60PubMed

27.

Kerb R, Bauer S, Brockmoeller J, et al. Urinary 6-p-hydroxycortisol excretion rate is affected by treatment with hypericum extract [abstract]. Eur J Clin Pharmacol 1997; 52Suppl.: A186

28.

Ernst E. Second thoughts about safety of St John’s wort [published erratum appears in Lancet 2000 Feb 12; 355 (9203): 580]. Lancet 1999 Dec 11; 354(9195): 2014–6PubMedCrossRef

29.

Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000 Feb 12; 355(9203): 548–9PubMedCrossRef

30.

Federal Institute for Drugs and Medical Devices. Announcement regarding drug authorisation and registration -clearance of drug-related safety risks, hearing, stage II. Human medicinal drugs containing Hypericum (St John’s wort) for oral application [in German]. BAnz 2000 Apr 4; 66

31.

Public statement on the risk of drug interactions with Hypericum perforatum (St John’s wort) and antiretroviral medicinal products. London: European Medicines Evaluation Agency, 28 Feb 2000 [online]. Available from URL: http://www.eudra.org/emea.html [Accessed 2003 Jul 31]

32.

St John’s wort may influence other medication. Uppsala: Medical Products Agency, 2002 Feb 6 [online]. Available from URL: http://www.mpa.se [Accessed 2003 Jul 31]

33.

Breckenridge A. Important interactions between St John’s wort (Hypericum perforatum) preparations and prescribed medicines. London: Medicines Control Agency -Committee on Safety of Medicines, 2000 Feb 29 [online]. Available from URL: http://www.mca.gov.uk [Accessed 2003 Jul 31]

34.

Lumpkin MM, Alpert S. FDA public health advisory: risk of drug interactions with St John’s wort and indinavir and other drugs. US Food and Drug Administration -Center for Drug Evaluation and Research, 2000 Feb 10 [online]. Available from URL: http://www.fda.gov [Accessed 2003 Jul 31]

35.

Mehta U. Potentially serious drug interactions between St John’s Wort and other medicines [letter]. S Afr Med J 2000 Jul; 90(7): 698PubMed

36.

Potential drug interactions with St John’s wort. Health Canada, 2000 Apr 7 [online]. Available from URL: http://www.hcsc.gc.ca/english/index.html [Accessed 2003 Jul 31]

37.

Bon S, Hartmann K, Kuhn M. Johanniskraut: Ein Enzyminduktor? Schweizer Apothekerzeitung 1999; 16: 535–6

38.

Henderson L, Yue QY, Bergquist C, et al. St John’s wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002 Oct; 54(4): 349–56PubMedCrossRef

39.

Yue QY, Bergquist C, Gerden B. Safety of St John’s wort (Hypericum perforatum). Lancet 2000 Feb 12; 355(9203): 576–7PubMedCrossRef

40.

Rey JM, Walter G. Hypericum perforatum (St John’s wort) in depression: pest or blessing? Med J Aust 1998 Dec 7-21; 169(11-12): 583–6PubMed

41.

Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability [published erratum appears in Br J Clin Pharmacol 2002 Apr; 53 (4): 449P]. Br J Clin Pharmacol 2001 Nov; 52(5): 587–95PubMedCrossRef

42.

Ladner DP, Klein SD, Steiner RA, et al. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. Br J Dermatol. 2001 Apr; 144(4): 916–8PubMedCrossRef

43.

Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St John’s wort with cyclosporine [letter]. Lancet 2000 May 27; 355(9218): 1912PubMedCrossRef

44.

Karliova M, Treichel U, Malago M, et al. Interaction of Hypericum perforatum (St John’s wort) with cyclosporine A metabolism in a patient after liver transplantation. J Hepatol 2000 Nov; 33(5): 853–5PubMedCrossRef

45.

Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother 2000 Sep; 34(9): 1013–6PubMedCrossRef

46.

Beckman SE, Sommi RW, Switzer J. Consumer use of St John’s wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000 May; 20(5): 568–74PubMedCrossRef

47.

Lantz MS, Buchalter E, Giambanco V. St John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999 Spring; 12(1): 7–10PubMedCrossRef

48.

Prost N, Tichadou L, Rodor F, et al. Interaction millepertuis-venlafaxine. Presse Med 2000 Jul 1; 29(23): 1285–6PubMed

49.

Dannawi M. Possible serotonin syndrome after combination of buspirone and St John’s Wort [letter]. J Psychopharmacol 2002 Dec; 16(4): 401PubMedCrossRef

50.

Gordon JB. SSRIs and St John’s Wort: possible toxicity? Am Fam Physician 1998 Mar 1; 57(5): 950–3PubMed

51.

Barbenel DM, Yusufi B, O’Shea D, et al. Mania in a patient receiving testosterone replacement post-orchidectomy taking St John’ wort and sertraline. J Psychopharmacol 2000; 14(1): 84–6PubMedCrossRef

52.

Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv 1999 Jul; 50(7): 969–70PubMed

53.

Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St John’s wort. J Clin Anesth 2000 Sep; 12: 498–9PubMedCrossRef

54.

Crowe S, McKeating K. Delayed emergence and St John’s wort. Anesthesiology 2002 Apr; 96(4): 1025–7PubMedCrossRef

55.

Ahmed SM, Banner NR, Dubrey SW. Low cyclosporine-A level due to Saint-John’s-wort in heart transplant patients [letter]. J Heart Lung Transplant 2001 Jul; 20(7): 795795PubMedCrossRef

56.

Alscher DM, Klotz U. Drug interaction of herbal tea containing St John’s wort with cyclosporine. Transpl Int. 2003 Jul; 16(7): 543–4PubMedCrossRef

57.

Mandelbaum A, Pertzborn F, Martin-Facklam M, et al. Unexplained decrease of cyclosporine trough levels in a compliant renal transplant patient. Nephrol Dial Transplant 2000; 15: 1473–4PubMedCrossRef

58.

Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St John’s wort) after organ transplantation. Am J Kidney Dis 2001 Nov; 38(5): 1105–7PubMedCrossRef

59.

Turton-Weeks SM, Barone GW, Gurley BJ, et al. St John’s wort: a hidden risk for transplant patients. Prog Transplant 2001 Jun; 11(2): 116–20PubMed

60.

Beer AM, Ostermann T. St John’s wort: interaction with cyclosporine increases risk of rejection for the kidney transplant and raises daily cost of medication [in German]. Med Klin (Munich) 2001 Aug 15; 96(8): 480–3CrossRef

61.

Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporine A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation 2000 May 27; 69(10): 2229–30PubMedCrossRef

62.

Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporine. Int J Clin Pharmacol Ther 2000 Oct; 38(10): 500–2PubMed

63.

de Maat MM, Hoetelmans RM, Mathot RA, et al. Drug interaction between St John’s wort and nevirapine. AIDS 2001 Feb 16; 15(3): 420–1PubMedCrossRef

64.

Ratz AE, von Moos M, Drewe J. St John’s wort: a pharmaceutical with potentially dangerous interactions [in German]. Schweiz Rundsch Med Prax 2001 May 10; 90(19): 843–9

65.

Rossler MC, Wirthner D, Schnegg A, et al. Une grossesse sous Implanon®, la faute au millepertuis? Gynakol Geburtshilfliche Rundsch 2003; 43: 186–7

66.

Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on selfmedication with St John’s wort despite hormonal contraception. Br J Clin Pharmacol 2003 Jan; 55(1): 112–3PubMedCrossRef

67.

Vorsicht: “Pillen”-Versager durch Johanniskraut. Arznei-Telegramm 2001; 32 (3): 35

68.

Eich-Hochli D, Oppliger R, Golay KP, et al. Methadone maintenance treatment and St John’s Wort: a case report. Pharmacopsychiatry 2003 Jan; 36(1): 35–7PubMedCrossRef

69.

Bolley R, Zulke C, Kammerl M, et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort [letter]. Transplantation 2002 Mar 27; 73(6): 1009PubMedCrossRef

70.

Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St John’s wort and theophylline. Ann Pharmacother 1999 Apr; 33(4): 502PubMedCrossRef

71.

Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001 Dec; 70(6): 518–24PubMedCrossRef

72.

Bauer S, Stormer E, Johne A, et al. Alterations in cyclosporine A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol 2003 Feb; 55(2): 203–11PubMedCrossRef

73.

Mai I, Stormer E, Bauer S, et al. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003 Apr; 18(4): 819–22PubMedCrossRef

74.

Mathijssen RHJ, Verweij J, de Bruijn P, et al. Effects of St John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002 Aug 21; 94(16): 1247–9PubMedCrossRef

75.

Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004 Feb; 75(2): P96CrossRef

76.

Tannergren C, Engman H, Knutson L, et al. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004 Apr; 75(4): 298–309PubMedCrossRef

77.

Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet 2000 Feb 12; 355(9203): 547–8PubMedCrossRef

78.

Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John’s wort (Hypericum perforatum). J Clin Psychopharmacol 2002 Feb; 22(1): 46–54PubMedCrossRef

79.

Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004 May; 57(5): 592–9PubMedCrossRef

80.

Maurer A, Johne A, Bauer S, et al. Interaction of St John’s wort extract with phenprocoumon [abstract]. Eur J Clin Pharmacol 1999; 55: A22

81.

Kawaguchi A, Ohmori M, Tsuruoka S, et al. Effect of St John’s wort on the pharmacokinetics and pharmacodynamics of quazepam [abstract]. Clin Pharmacol Ther 2003 Feb; 73(2): 44CrossRef

82.

Hall SD, Wang Z, Huang SM, et al. The interactions between St John’s wort and an oral contraceptive. Clin Pharmacol Ther 2003 Dec; 74(6): 525–35PubMedCrossRef

83.

Pfrunder A, Schiesser M, Gerber S, et al. Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003 Dec; 56(6): 683–90PubMedCrossRef

84.

Brattström A. Der Johanniskrautextrakt ZE 117. Dtsch Apoth Ztg 2002 Jul 25; 142(30): 97–100

85.

Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999 Oct; 66(4): 338–45PubMedCrossRef

86.

Durr D, Stieger B, Kullak-Ublick GA, et al. St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000 Dec; 68(6): 598–604PubMedCrossRef

87.

Arold G, Donath F, Maurer A, et al. The influence of St John’s wort extract (St John’s wort, Esbericum capsules) on the pharmacokinetics of alprazolam, caffeine, tolbutamide and digoxin in man. In: 5th EACPT Congress; 2001; Odense. Pharmacol Toxicol 2001; 89Suppl. 1: 74–5

88.

Mueller SC, Uehleke B, Woehling H, et al. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004 Jun; 75(6): 546–57PubMedCrossRef

89.

Wang LS, Zhou G, Zhu B, et al. St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004 Mar; 75(3): 191–7PubMedCrossRef

90.

Burstein AH, Horton RL, Dunn T, et al. Lack of effect of St John’s Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000 Dec; 68(6): 605–12PubMedCrossRef

91.

Wilkinson GR. Pharmacokinetics. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 3–29

92.

Rendic S, Di Carlo FJ. Human cytochrome P450 enzyme: a status report summarizing their reactions, substrates, induction, and inhibitors. Drug Metab Rev 1997; 29: 413–580PubMedCrossRef

93.

Bodo A, Bakos E, Szeri F. The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol Lett 2003 Apr 11; 140–141: 133-43

94.

Roby CA, Anderson GD, Kantor E, et al. St John’s Wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000 May; 67(5): 451–7PubMedCrossRef

95.

Wenk M, Todesco L, Krahenbuhl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol 2004 Apr; 57(4): 495–9PubMedCrossRef

96.

Bauer S, Stormer E, Kerb R, et al. Differential effects of St John’s wort (hypericum perforatum) on the urinary excretion of D-glucaric acid and 6-p-hydroxycortisol in healthy volunteers. Eur J Clin Pharmacol 2002; 58: 581–5PubMedCrossRef

97.

Wang Z, Gorski JC, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001 Oct; 70(4): 317–26PubMed

98.

Dresser GK, Schwarz UI, Wilkinson GR, et al. St John’s wort induces intestinal and hepatic CYP3A4 and p-glycoprotein in healthy volunteers [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): 23

99.

Xie R, Tan L, Polasek EC, et al. CYP3A and p-glycoprotein induction with St John’s wort in healthy volunteers of selected ethnic populations [abstract]. Clin Pharmacol Ther 2003 Feb; 73(2): 93CrossRef

100.

Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002 Sep; 72(3): 276–87PubMedCrossRef

101.

Smith M, Lin KM, Zheng YP. An open trial of nifedipine-herb interactions: nifedipine with St John’s wort, ginseng or Ginkgo biloba [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): P86

102.

Ereshefsky B, Gewertz N, Lam YWF, et al. Determination of St John’s wort differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology [poster no. 130]. 39th Annual NCDEU Meeting; 1999 Jun 3, Boca Raton (FL)

103.

Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000 Jan 21; 66(9): PL133–9PubMedCrossRef

104.

Markowitz JS, Donovan JL, DeVane CL, et al. Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003 Sep 17; 290(11): 1500–4PubMedCrossRef

105.

Roby CA, Dryer DA, Burstein AH. St John’s wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J Clin Psychopharmacol 2001 Oct; 21(5): 530–2PubMedCrossRef

106.

Gewertz N, Ereshefsky B, Lam YWF, et al. Determination of the differential effects of St John’s wort on the CYP1A2 and NAT2 metabolic pathways using caffeine probe methodology [poster no. 131]. 39th Annual NCDEU Meeting; 1999 Jun 3, Boca Raton (FL)

107.

Chang M, Tybring G, Dahl ML, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 1995 May; 39(5): 511–8PubMedCrossRef

108.

Kaminsky LS, de Morais SM, Faletto MB, et al. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Mol Pharmacol 1993 Feb; 43(2): 234–9PubMed

109.

Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline Ndemethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998 Feb; 38(2): 112–21PubMed

110.

Hamman MA, Wang Z, Honig P, et al. Effects of acute and chronic St John’s wort (St John’s wort ) administration on fexofenadine (FEX) disposition [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): 53

111.

Wang Z, Hamman MA, Huang SM, et al. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002 Jun; 71(6): 414–20PubMedCrossRef

112.

Schwarz UI, Hanso H, Dreser GK, et al. St John’s wort reduces oral bioavailability of talinolol in healthy volunteers [abstract]. Clin Pharmacol Ther 2002 Feb; 71(2): 33

113.

Drewe J, Gutmann H, Toeroek M, et al. Mechanismen der Interaktionen mit Johanniskrautextrakten. In: Rietbrock N, editor. Phytopharmaka VI: Forschung und klinische Anwendung. Darmstadt: Steinkopff, 2000: 75–81

114.

Hennessy M, Kelleher D, Spiers JP, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002 Jan; 53(1): 75–82PubMedCrossRef

115.

Hehl EM, Muller S, Wutzke KD, et al. Influence of St John’s wort on oro-coecal transit time in healthy volunteers [abstract]. From the 5th EACPT Congress; 2001, Odense. Pharmacol Toxicol 2001; 89Suppl. 1: 76

116.

Bray BJ, Perry NB, Menkes DB, et al. St John’s wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002 Mar; 66(1): 27–33PubMedCrossRef

117.

Cantoni L, Rozio M, Mangolini A, et al. Hyperforin contributes to the Hepatic CYP3A-inducing effect of hypericum perforatum extract in the mouse. Toxicol Sci 2003 Sep; 75: 25–30PubMedCrossRef

118.

Bray BJ, Brennan NJ, Perry NB, et al. Short term treatment with St John’s wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse. Life Sci 2002 Feb 1; 70(11): 1325–35PubMedCrossRef

119.

Noeldner M, Chatterjee S. Effects of two different extracts of St John’s wort and some of their constituents on cytochrome P450 activities in rat liver microsomes. Pharmacopsychiatry 2001 Jul; 34Suppl. 1: S108–10CrossRef

120.

Gerloff T, Störmer E, Mrozikiewicz PM, et al. Hypericum perforatum (St John’s wort) has no effect on protein expression of intestinal p-glycoprotein (MDR1) in the rat. Presented at the Joint Meeting of the VII. World Conference on Clinical Pharmacology and Therapeutics and 4th Congress of the European Association of Clinical Pharmacology and Therapuetics; 2000 Jul 15-20; Florence: 194

121.

Dürr D, Stieger B, Meier PJ, et al. St John’s wort (St John’s wort) and dexamethasone (DEX) selectively induce hepatic Oatp2 expression in rats. In: 5th European Association for Clinical Pharmacology and Therapeutics Congress; 2001; Odense. Pharmacol Toxicol 2001; 89Suppl. 1: 73

122.

Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St John’s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000 Jul; 294(1): 88–95PubMed

123.

Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000 Jul; 7(4): 273–82PubMedCrossRef

124.

Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic acitivity. Life Sci 2002 Aug 16; 71(13): 1579–89PubMedCrossRef

125.

Schwarz D, Kisselev P, Roots I. St John’s wort extracts and some of their constituents potently inhibit ultimate carcinogen 795 formation from benzo[a]pyrene-7,8-dihydrodiol by human CYP1A1. Cancer Res 2003 Nov 15; 63(22): 8062–8PubMed

126.

Perloff MD, Stormer E, von Moltke LL, et al. Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm Res 2003 Aug; 20(8): 1177–83PubMedCrossRef

127.

Carson SW, Hill-Zabala CE, Blalock SB, et al. Constituents of St John’s wort inhibit cytochrome P450 3A4 and P450 reductase activity in human liver microsomes [abstract]. Clin Pharmacol Ther 2000 Feb; 67(2): 99

128.

Carson SW, Hill-Zabala CE, Roberts SH, et al. Inhibitory effect of methanolic solution of St John’s wort (Hypericum perforatum) on cytochrome P450 3A4 activity in human liver microsomes [abstract]. Clin Pharmacol Ther 2001 Feb; 69(2): 8

129.

Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002 Jun; 32(6): 451–78PubMedCrossRef

130.

Krusekopf S, Roots I, Kleeberg U. Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. Eur J Pharmacol 2003 Apr 11; 466(1-2): 7–12PubMedCrossRef

131.

Moore LB, Goodwin B, Jones SA, et al. St John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000 Jun 20; 97(13): 7500–2PubMedCrossRef

132.

Karyekar CS, Eddington ND, Dowling TC. Effect of St John’s Wort extract on intestinal expression of cytochrome P4501A2: studies in LS180 cells. J Postgrad Med 2002 Apr-Jun; 48(2): 97–100PubMed

133.

Peebles KA, Baker RK, Kurz EU, et al. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St John’s wort (Hypericum perforatum). Biochem Pharmacol 2001 Oct 15; 62(8): 1059–70PubMedCrossRef

134.

Watkins RE, Maglich JM, Moore LB, et al. A crystal structure of human PXR in complex with the St John’s wort compound hyperforin. Biochemistry 2003 Feb 18; 42(6): 1430–8PubMedCrossRef

135.

Perloff MD, von Moltke LL, Stormer E, et al. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001 Dec; 134(8): 1601–8PubMedCrossRef

136.

Troutman MD, Thakker DR, Carson SW, et al. Activation and inhibition of P-glycoprotein (P-gp) mediated efflux of digoxin by St John’s wort extract [abstract]. AAPS Pharm Sci 2000; 4: 948. Available from URL: http://www.aapspharmsci.org/ [Accessed 2003 Jul 20]

137.

Sonoda J, Rosenfeld JM, Xu L, et al. A nuclear receptormediated xenobiotic response and its implication in drug metabolism and host protection. Curr Drug Metab 2003 Feb; 4(1): 59–72PubMedCrossRef

138.

Kerb R, Brockmoller J, Staffeldt B, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40: 2087–93PubMed

139.

Biber A, Fischer H, Romer A, et al. Oral bioavailability of hyperforin extracts in rats and human volunteers. Pharmacopsychiatry 1998; 31: 36–43PubMedCrossRef

140.

Wentworth JM, Agostini M, Love J, et al. St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000 Sep; 166(3): R11–6PubMedCrossRef

141.

Chen Y, Ferguson SS, Negishi M, et al. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor (PXR). J Pharmacol Exp Ther 2004 Feb; 308(2): 495–501PubMedCrossRef

142.

Parker V, Wong AH, Boon HS, et al. Adverse reactions to St John’s Wort. Can J Psychiatry 2001 Feb; 46(1): 77–9PubMed

143.

Sanders-Bush E, Mayer SE. 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 278–81

144.

Kim RB, Wandel C, Leake B, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999 Mar; 16(3): 408–14PubMedCrossRef

145.

Kharasch ED, Thummel KE. Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology 1993 Oct; 79(4): 795–807PubMedCrossRef

146.

Thummel KE, Kharasch ED, Podoll T, et al. Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 1993 Mar-Apr; 21(2): 350–7PubMed

147.

Loi CM, Day JD, Jue SG, et al. Dose-dependent inhibition of theophylline metabolism by disulfiram in recovering alcoholics. Clin Pharmacol Ther 1989; 45(5): 476–86PubMedCrossRef

148.

Morimoto T, Kotegawa T, Tsutsumi K, et al. Effect of St John’s wort on the pharmacokinetics of theophylline in healthy volunteers. J Clin Pharmacol 2004; 44(1): 95–101PubMedCrossRef

149.

Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P450. Br J Clin Pharmacol 1995; 39: 321–6PubMedCrossRef

150.

Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002 Oct; 23(5): 687–702PubMedCrossRef

151.

Xie W, Evans RM. Orphan nuclear receptors: the exotics of xenobiotics. J Biol Chem 2001 Oct 12; 276(41): 37739–42PubMed

152.

Melzer M, Fuhrken D, Kolkmann R. Hyperforin im Johanniskraut. Dtsch Apoth Ztg 1998; 138: 4754–60

153.

Conseil G, Baubichon-Cortay H, Dayan G, et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A 1998 Aug 18; 95(17): 9831–6PubMedCrossRef

154.

Leslie EM, Mao Q, Oleschuk CJ, et al. Modulation of multidrug resistance protein 1 (MRP1/ABCC1) transport and atpase activities by interaction with dietary flavonoids. Mol Pharmacol 2001 May; 59(5): 1171–80PubMed

155.

Zhou S, Gao Y, Jiang W, et al.1171-80 Interactions of herbs with cytochrome P450. Drug Metab Rev 2003 Feb; 35(1): 35–98PubMedCrossRef

156.

Meier B. Comparing phytopharmaceuticals: the example of St John’s wort. Adv Ther 2001 Jan-Feb; 18(1): 35–46PubMedCrossRef

157.

Chatterjee SS, Noldner M, Koch E, et al. Antidepressant activity of hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 1998 Jun; 31Suppl. 1: 7–15PubMedCrossRef

158.

Groning R, Breitkreutz J, Muller RS. Physico-chemical interactions between extracts of Hypericum perforatum L. and drugs. Eur J Pharm Biopharm 2003 Sep; 56(2): 231–6PubMedCrossRef

159.

Wang EJ, Barecki-Roach M, Johnson WW. Quantitative characterization of direct P-glycoprotein inhibition by St John’s wort constituents hypericin and hyperforin. J Pharm Pharmacol 2004 Jan; 56(1): 123–8PubMedCrossRef

160.

Komoroski BJ, Zhang S, Cai H, et al. Induction and inhibition of cytochromes p450 by the St John’s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004 May; 32(5): 512–8PubMedCrossRef

161.

Heinemeyer G, Roots I, Lestau P, et al. D-glucaric acid excretion in critical care patients -comparison with 6-beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy. Br J Clin Pharmacol 1986 Jan; 21(1): 9–18PubMedCrossRef

162.

Roots I, Holbe R, Hovermann W, et al. Quantitative determination by HPLC of urinary 6beta-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol 1979 Aug; 16(1): 63–71PubMedCrossRef

163.

Hildebrandt AG, Roots I, Speck M, et al. Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo. Eur J Clin Pharmacol 1975 Jun 13; 8(5): 327–36PubMedCrossRef

164.

Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984 Sep; 18(3): 401–10PubMedCrossRef

165.

Ohnhaus EE, Kirchhof B, Peheim E. Effect of enzyme induction on plasma lipids using antipyrine, phenobarbital, and rifampicin. Clin Pharmacol Ther 1979 May; 25(5 Pt 1): 591–7PubMed

166.

Perucca E, Richens A. Reversal by phenytoin of carbamazepineinduced water intoxication: a pharmacokinetic interaction. J Neurol Neurosurg Psychiatry 1980 Jun; 43(6): 540–5PubMedCrossRef

167.

Christiansen J, Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurol Scand 1973; 49(4): 543–6PubMedCrossRef

168.

Franklin M, Reed A, Murck H. Sub-chronic treatment with an extract of Hypericum perforatum (St John’s wort) significantly reduces cortisol and corticosterone in the rat brain. Eur Neuropsychopharmacol 2004 Jan; 14(1): 7–10PubMedCrossRef

169.

Lam FC, Liu R, Lu P, et al. Beta-Amyloid efflux mediated by pglycoprotein. J Neurochem 2001 Feb; 76(4): 1121–8PubMedCrossRef

170.

Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002 Oct; 12(7): 535–41PubMedCrossRef

171.

Xie W, Radominska-Pandya A, Shi Y, et al. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids. Proc Natl Acad Sci U S A 2001 Mar 13; 98(6): 3375–80PubMedCrossRef

172.

Tabb MM, Sun A, Zhou C, et al. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor, SXR. J Biol Chem 2003 Nov 7; 278(45): 43919–27PubMedCrossRef

173.

Walter G, Rey JM, Harding A. Psychiatrists’ experience and views regarding St John’s wort and “alternative” treatments. Aust N Z J Psychiatry 2000 Dec; 34(6): 992–6PubMedCrossRef

174.

Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001 Jul 11; 286(2): 208–16PubMedCrossRef

175.

Hodges PJ, Kam PC. The peri-operative implications of herbal medicines. Anaesthesia 2002 Sep; 57(9): 889–99PubMedCrossRef

176.

Skinner CM, Rangasami J. Preoperative use of herbal medicines: a patient survey. Br J Anaesth 2002 Nov; 89(5): 792–5PubMedCrossRef

177.

de Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003; 42(3): 223–82PubMedCrossRef

178.

Chabner BA, Ryan DP, Paz-Ares L, et al. Antineoplastic agents. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 1389–1459

179.

Vecht CJ, Wagner GL, Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2003 Jul; 2(7): 404–9PubMedCrossRef

180.

Majerus PW, Tollefsen DM. Anticoagulant, thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. New York: MacGraw-Hill, 2001: 1519–38

181.

Shader RI, Oesterheld JR. Contraceptive effectiveness: cytochromes and induction. J Clin Psychopharmacol 2000 Apr; 20(2): 119–21PubMedCrossRef

182.

Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988 May; 33(5): 500–8PubMed

183.

Bolt HM, Bolt M, Kappus H. Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. Acta Endocrinol (Copenh) 1977 May; 85(1): 189–97

184.

Murphy PA. St John’s wort and oral contraceptives: reasons for concern? J Midwifery Womens Health 2002 Nov-Dec; 47(6): 447–50PubMedCrossRef

185.

Murphy PA. Examination of the effect of St John’s Wort on contraceptive efficacy [oral presentation]. Presented at the 40th Annual Meeting, Association of Reproductive Health Professionals; 2003 Sep 11, La Jolla (CA)

186.

Irish Medicines Board (IMB). Drug safety newsletter. 9th ed. no. 10. Dublin: IMB, 2000: 3

187.

Swissmedic. Interaktionspotential von Spezialitaten mit Hypericum perforatum. Abschluss des Gruppenrevisionsverfahrens [Interaction potential of drug preparations containing Hypericum perforatum. Completion of the safety risk clearance procedure]. Swissmedic J 2002; 1: 7

188.

Swissmedic. Interaktionspotenzial von Arzneimitteln mit Hypericum perforatum — Verfügung bezüglich der MRAuflagen im Rahmen des Überprufungsverfahrens nach Art. [Mandate concerning monitored-release imposts regarding the interaction potential of drug preparations containing Hypericum perforatum. Registered letter to St John’s wort drug manufacturers. 16 Abs. 2 des Heilmittelgesetzes (HMG) und Art. 58 Abs. 3 HMG]. Swissmedic 2003 Sep 19

189.

Sorensen JM. Herb-drug, food-drug, nutrient-drug, and drug-drug interactions: mechanisms involved and their medical implications. J Altern Complement Med 2002 Jun; 8(3): 293–308PubMedCrossRef

190.

Deferme S, Augustijns P. The effect of food components on the absorption of P-gp substrates: a review. J Pharm Pharmacol 2003 Feb; 55(2): 153–62PubMedCrossRef

191.

Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother 2002 Dec; 36(12): 1893–6PubMedCrossRef

192.

Koumaravelou K, Adithan C, Shashindran CH, et al. Effect of honey on carbamazepine kinetics in rabbits. Indian J Exp Biol 2002 May; 40(5): 560–3PubMed

193.

Koumaravelou K, Adithan C, Shashindran CH, et al. Influence of honey on orally and intravenously administered diltiazem kinetics in rabbits. Indian J Exp Biol 2002 Oct; 40(10): 1164–8PubMed

194.

Tsunoda SM, Harris RZ, Christians U, et al. Red wine decreases cyclosporine bioavailability. Clin Pharmacol Ther 2001 Nov; 70(5): 462–7PubMedCrossRef

Title: Drug Interactions with St John’s Wort
Mechanisms and Clinical Implications
Author: Dr Marcus Mannel
Publication date: 01-09-2004
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 11/2004
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200427110-00003

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Drug Interactions with St John’s Wort

Mechanisms and Clinical Implications

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2004

Frequency and Preventability of Adverse Drug Reactions in Paediatric Patients

Quantifying Adverse Drug Events

Micro-Electrode Arrays in Cardiac Safety Pharmacology

A Benefit-Risk Assessment of Baclofen in Severe Spinal Spasticity